Testing paclitaxel and ramucirumab with or without zanidatamab for HER2+ stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests adding a new drug (zanidatamab) to standard chemotherapy (paclitaxel and ramucirumab) for people with advanced HER2-positive stomach, gastroesophageal junction, or esophageal cancer that has worsened after previous treatment. It aims to see if the combination works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced stomach, gastroesophageal junction, or esophageal cancer that cannot be removed by surgery or has spread to other parts of the body.
- Your cancer is HER2-positive (a specific protein marker) confirmed by a central lab.
- You have already tried and your cancer progressed on a treatment that included trastuzumab (Herceptin) and platinum chemotherapy.
- You are at least 18 years old, in generally good physical condition (ECOG 0 or 1), and expected to live at least 12 weeks.
- You are willing to provide blood and tumor samples for research, and can travel for treatment and follow-up visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests new drug combinations for people with advanced stomach or esophageal cancer that worsened after first treatment. It aims to find better options for those whose tumors lack HER2.
This trial tests a new combination of targeted therapy (zanidatamab), immunotherapy (pembrolizumab), and chemotherapy for people with HER2-positive and PD-L1-positive advanced stomach or gastroesophageal cancer. It aims to see if this combination is more effective than current treatments.
This study tests two different treatment options for advanced stomach or gastroesophageal junction cancer that has grown after earlier chemotherapy. One option combines a targeted therapy (ramucirumab) with a chemotherapy pill (trifluridine/tipiracil), and the other is a standard chemotherapy drug (paclitaxel). The goal is to see which approach works better for people whose cancer has progressed, with the hope of improving outcomes.
This trial tests a combination of anti-cancer medicines for HER2-positive advanced stomach cancer that has already been treated once. It may help shrink tumors and slow the disease by targeting HER2 and blocking tumor blood supply.
This trial tests a new drug called zanidatamab given together with standard chemotherapy before surgery for a type of stomach or junction cancer that is HER2-positive (has a specific protein). The goal is to see if this combination can shrink the tumor and improve the chances of successful surgery.
This trial tests a new way to deliver chemotherapy directly into the belly for stomach cancer that has spread to the lining of the abdomen (peritoneal metastases). It also combines two standard chemotherapy drugs. The goal is to see if this approach can help people whose cancer progressed after first treatment.
Hear when a new Gastroesophageal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.